BerGenBio

Regulatory Filings • Aug 22, 2023

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BERGEN, Norway, August 22, 2023- BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical needs, announcedtoday that additional clinical data of

bemcentinib in combination with chemotherapy and with immunotherapy in Non-Small

Cell Lung Cancer (NSCLC) have been recently published and accepted for

presentation at two upcoming international oncology conferences:

· Comprehensive results from the investigator led trial of bemcentininb +

docetaxel in previously treated NSCLC patients (Study BGBIL005) were published

in the August 2023 issue of Lung Cancer. "Phase 1 trial of bemcentinib (BGB324),

a first-in-class, selective AXL inhibitor, with docetaxel in patients with

previously treated advanced non-small cell lung cancer." Lung Cancer 182 (2023)

The trial was led by David Gerber, MD., Professor at the UT Southwestern Harold

C. Simmons Comprehensive Cancer Center.

· The abstract "Bemcentinib + Pembrolizumab show promising efficacy in

metastatic NSCLC harbouring mutations associated with poor prognosis:

Exploratory sub-analysis from the BGBC008 trial (NCT03184571)" has been accepted

for posterpresentationat the SITC 38th Annual Meeting, to be held November 3-5,

2023,in San Diego, CA (Abstract #598).

· The abstract "Final top-line results of the BGBC008 phase 2, multicenter

study of bemcentinib and pembrolizumab (bem+pembro) in 2nd line (2L) advanced

non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)"has been

accepted for poster presentation at the ESMO Congress 2023, to be held October

20-24, 2023, in Madrid, Spain (Abstract #5343)

"The accumulating evidence supporting the potential role of bemcentinib in NSCLC

aligns with our strategic focus on this disease where a large portion of

patients still have very poor clinical outcome from existing therapies" said

Martin Olin, Chief Executive Officer of BerGenBio. "The publication of data in a

prestigious peer reviewed publication and at ESMO and SITC provides us with the

opportunity to share our data with a broad audience of oncologists and key

opinion leaders in the field of NSCLC and the pharmaceutical industry."

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate, bemcentinib, a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visitwww.bergenbio.com

This information is subject to the disclosure requirements pursuant to MAR

article 17 and section 5-12 of the Norwegian Securities Trading Act.